What factors do you take into account when deciding which gene expression assay to utilize when making adjuvant treatment decisions in patients with non-metastatic breast cancer?  

Oncotype DX has been validated in multiple large prospective trials and has demonstrated predictive value, while MammaPrint has not been validated to be predictive for chemotherapy benefit but only identifies low-risk biology. Oncotype DX has been validated in node-negative and 1–3 node-positi...